Member Info for Scaffers

Pokerchips, there are only 36.92m shares in free float and able to be traded :)))

The next target price to aim for is predicted to be 91p on my 60 minute point and figure chart. After that - onwards and upwards as more news comes in. :)

Just to confuse matters more Rodney, Kromek KMK are the ones who received the funding whish was announced on Wednesday. Ther's no mention of any Genedrive collaberation so Proactive Investor seems to have their story mixed up?

Sorry about that Rodney, it came up as a new story yasterday on Proactive investor's website.

https://www.proactiveinvestors.com/companies/news/28427/clifton-star-resources-unveils-excellent-gold-recovery-in-biox-albion-tests--28427.html

Epistem Holdings signs up to help police with DNA identification
Biotech firm Epistem Holdings (LON:EHP) is collaborating with the National Policing Improvement Agency to help develop a human DNA identification system.

The two organisations will evaluate Epistem’s Genedrive molecular device as part of the NPIA’s ADAPT (Accelerated DNA Profiling Technology) programme.

The NPIA was set up to provide critical national services to support frontline policing. It is aimed at helping the police to save money and operate efficiently.

The organisation plans to use Genedrive to target the ‘amelogenin’ sex gene and other single tandem repeats (STRs) that create the human DNA fingerprint. If trials are successful, the NPIA could use Genedrive to enable rapid and accurate DNA analysis at a crime scene, leading to improved speed of identification and reduced cost.

Epistem says its Genedrive technology provides a “breakthrough in molecular diagnostic testing” by providing a rapid, low cost, simple-to-use device with high sensitivity and specificity. Developed as a handheld device, it brings a “point of need” approach to disease diagnosis and identification across a broad spectrum of DNA-related areas from human identification for policing purposes to pharmacogenomic use in oncology, virology, ophthalmology and the detection of infectious diseases.

The ADAPT evaluation programme in the NPIA is planned to continue into next year, and if successful it will be rolled out into a number of police forces in the UK.

From The Telegraph
RSI: 38 No clear indication according to RSI.
Stochastic: 30 No clear indication according to Stochastic.
MACD: MACD is above the MACD signal which might indicate a positive momentum in stock
ADX: 27 This could indicate that stock has a strong negative trend.
SMA 20 & 50: The last 20 day's moving average (48.52) is below the last 50 day's moving average (74.85). This is theoretically a negative sign.
SMA 100 & 200: The last 100 day's moving average (96.22) is above the last 200 day's moving average (75.37). This is theoretically a positive sign.

Expected USA green stimulus package under the new administration?

Now up 3p 6%

Genedrive PLC - near patient molecular diagnostics company - Notes completion of the Antibiotic Induced Hearing Loss implementation study into the use of the genetic test in an NHS neonatal intensive care setting. Company adds: "The Genedrive MT-RNR1 ID Kit has been used over the past 11 months in a trial of what is thought to be a world first use of a genetic test in a neonatal intensive care setting. The Genedrive assay has been used at Manchester University NHS Foundation Trust and Liverpool Women's Hospital to screen babies before administering certain antibiotics that are known to cause deafness in infants." Chief Executive David Budd says completion of study is "major milestone".